Study details
Enrolling now
A Study of Enfortumab Vedotin in People With Urothelial Carcinoma of the Upper Urinary Tract
Memorial Sloan Kettering Cancer Center
NCT IDNCT05868265ClinicalTrials.gov data as of Apr 2026
Phase
Phase 2
Target enrollment
24
Study length
about 3 years
Ages
18+
Locations
8 sites in NJ, NY
What this study is about
This trial is testing whether enfortumab vedotin, a drug, is an effective and safe treatment for people with urothelial carcinoma of the upper urinary tract. Participants will not receive cisplatin chemotherapy or have standard surgery to remove their tumor.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take Enfortumab Vedotin
- 2.Undergo Radical surgery
Participation Burden
What's physically and logistically required of participants.
Logistics & Travel
In-person visits
Requires travel to a study site
Physical Intervention
Standard
How treatment is administered
Treatment Assignment
All receive treatment
Everyone gets the investigational treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Drug classes
enfortumab vedotin
Endpoints
Secondary: The rate of grade 3 - 4 toxicity
Procedures
surgery